Mild cognitive impairment in Parkinson's disease
Alison Jane Yarnall1, Lynn Rochester, David John Burn
1Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, Tyne and Wear NE4 5PL, UK. alison.yarnall@ncl.ac.uk
Age and Ageing
|July 23, 2013
Summary
Parkinson's disease mild cognitive impairment (PD-MCI) is common, often non-amnestic, and predicts dementia. Further research is needed to validate diagnostic criteria and understand progression factors for targeted interventions.
Area of Science:
- Neurology
- Neuroscience
- Cognitive Science
Background:
- Mild cognitive impairment (MCI) is increasingly recognized in the general population and linked to Alzheimer's disease risk.
- Mild cognitive impairment in Parkinson's disease (PD-MCI) is common and certain subtypes predict progression to Parkinson's disease dementia (PDD).
- Movement Disorder Society criteria now exist to characterize PD-MCI and its subtypes.
Purpose of the Study:
- To review the current understanding of PD-MCI, including its characteristics and diagnostic criteria.
- To highlight the differences between general MCI and PD-MCI, particularly subtype prevalence.
- To emphasize the need for further research, including longitudinal studies, to understand PD-MCI progression and validate diagnostic tools.
Main Methods:
- Review of existing literature and diagnostic criteria for PD-MCI.
- Comparison of PD-MCI subtypes with general MCI subtypes.
- Discussion of potential pathophysiological mechanisms underlying PD-MCI.
Main Results:
- Non-amnestic PD-MCI, characterized by executive and attention dysfunction, is more prevalent than amnestic MCI in the general population.
- The pathophysiology of PD-MCI is complex, involving neurotransmitter dysfunction, synaptic pathology, protein aggregation, and neuronal damage.
- Currently, no specific drug therapies exist for PD-MCI.
Conclusions:
- PD-MCI is a significant clinical entity requiring further investigation to validate diagnostic criteria and understand progression.
- Longitudinal studies in homogenous Parkinson's disease cohorts are crucial for prognostication and generalizability.
- Current management focuses on screening, excluding treatable causes, and cautious medication use.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...